A pivotal multi-country, multi-center pivotal Phase 2/3 study of Abivertinib in patients At-Risk Hospitalized COVID-19 Patients requiring oxygen support via non-invasive ventilation or high flow oxygen at baseline (category 5 patients)
Latest Information Update: 05 Apr 2022
At a glance
- Drugs Abivertinib (Primary)
- Indications COVID 2019 infections; Respiratory insufficiency
- Focus Registrational; Therapeutic Use
- Sponsors Sorrento Therapeutics
- 31 Mar 2022 According to a Sorrento Therapeutics media release, the company received clearance from the US FDA to initiate this study.
- 02 Nov 2021 New trial record